Recent studies have shown that CD103+ DCs are capable of delivering intact tumor antigens to peripheral lymph nodes, thereby priming tumor-specific CD8+ T cells and locally suppressing PD-L1 activity (52, 56). This evidence concerns the gene CD274 and neoplasm.